330 related articles for article (PubMed ID: 2655259)
21. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
Kurth K; Schroeder FH; Debruyne F; Senge T; Pavone-Macaluso M; de Pauw M; ten Kate F; Sylvester R
Prog Clin Biol Res; 1989; 303():481-90. PubMed ID: 2675005
[No Abstract] [Full Text] [Related]
23. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors.
Colombo R; Da Pozzo LF; Lev A; Salonia A; Rigatti P; Leib Z; Servadio C; Caldarera E; Pavone-Macaluso M
J Urol; 1998 Mar; 159(3):783-7. PubMed ID: 9474148
[TBL] [Abstract][Full Text] [Related]
24. [Long-term intravesical treatment with adriamycin in chemoprevention of recurrence of transurethrally resected urinary bladder cancers].
Flamm J; Grof F
Wien Med Wochenschr; 1987 Jul; 137(13):315-7. PubMed ID: 3114964
[TBL] [Abstract][Full Text] [Related]
25. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trail comparing doxorubicin hydrochloride, ethoglucid and TUR-alone.
Kurth KH; Debruyne FJ; Senge T; Carpentier PJ; Riedl H; Sylvester R; de Pauw M
Prog Clin Biol Res; 1985; 185B():135-42. PubMed ID: 3898138
[No Abstract] [Full Text] [Related]
27. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
28. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
29. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
Nomata K; Noguchi M; Kanetake H; Tsuda N; Hayashi M; Yamashita S; Sakuragi T; Kusaba Y; Shindo K;
Cancer Chemother Pharmacol; 2002 Oct; 50(4):266-70. PubMed ID: 12357299
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
Papatsoris AG; Deliveliotis C; Giannopoulos A; Dimopoulos C
Urol Int; 2004; 72(4):284-91. PubMed ID: 15153724
[TBL] [Abstract][Full Text] [Related]
31. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
DeBruyne FM; van der Meijden AP; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg JJ
Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
[TBL] [Abstract][Full Text] [Related]
32. [Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Schwaibold H; Klingenberger HJ; Huland H
Urologe A; 1994 Nov; 33(6):479-83. PubMed ID: 7817443
[TBL] [Abstract][Full Text] [Related]
33. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
[TBL] [Abstract][Full Text] [Related]
34. [Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?].
Kriegmair M; Waidelich R; Baumgartner R; Lumper W; Ehsan A; Hofstetter A
Urologe A; 1994 Jul; 33(4):276-80. PubMed ID: 7941172
[TBL] [Abstract][Full Text] [Related]
35. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
[TBL] [Abstract][Full Text] [Related]
36. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
37. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
Huncharek M; Kupelnick B
Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
[TBL] [Abstract][Full Text] [Related]
38. [Results of a randomized, double blind prospective study of intravesical chemoprophylaxis with 2 drugs: adriamycin and mitomycin; and 2 ways of initiating the instillations: early and late. Effect on recurrence and progression].
Iborra Juan I; Ricos Torrent JV; Monrós Lliso JL; Dumont Martínez R; Casanova Ramón-Borja J; Solsona Narbón E
Arch Esp Urol; 1992 Dec; 45(10):1001-7. PubMed ID: 1294028
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
Schulze M; Stotz N; Rassweiler J
J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
[TBL] [Abstract][Full Text] [Related]
40. [Primary superficial bladder carcinoma. Prognostic factors for recurrence].
Jiménez Cruz JF; Llopis Minguez B; Vera Donoso CD
Arch Esp Urol; 1990; 43 Suppl 2():139-47. PubMed ID: 2096775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]